SCHEMBL24118290

SCHEMBL24118290

C=C(CCNC(=O)c1ncccc1F)C(C)C(=O)Nc1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ EGLN2 Q96KS0 1/20 0.39
▸ EGLN1 Q9GZT9 1/20 0.39
▸ KMT2A Q03164 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ GAA P10253 2/20 0.38
▸ CTSA P10619 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ MLKL Q8NB16 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ DNMT3B Q9UBC3 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ KIT P10721 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24117971 0.79 KDM4E (0.48) RAB9ANPC1KMT2AMEN1GAA
SCHEMBL24118612 0.78 L3MBTL1 (0.40) RAB9ANPC1EGLN2EGLN1KMT2A
SCHEMBL24118386 0.78 MEN1 (0.42) KMT2AMEN1KDM4EL3MBTL1POLB
SCHEMBL24118254 0.78 FPR2 (0.48) RAB9AKMT2AMEN1KDM4EMAPT
SCHEMBL23593322 0.78 POLB (0.48) RAB9ANPC1KMT2AMEN1KDM4E
SCHEMBL24118272 0.78 MEN1 (0.44) KMT2AMEN1KDM4EMAPTPOLB
SCHEMBL24117957 0.78 GCGR (0.46) RAB9ANPC1KMT2AMEN1SMN1; SMN2
SCHEMBL24117949 0.78 IDO1 (0.53) KMT2AMEN1KDM4EL3MBTL1POLB
SCHEMBL24118233 0.76 IDO1 (0.56) KMT2AMEN1GAAMAPTPOLB
SCHEMBL24118338 0.76 GCGR (0.46) L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors MERCK SHARP & DOHME CORP. (US) 2021-12-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393600-A1 Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors IDO1, IDO2, TPH1 RAB9A 2866/4885NPC1 1240/4885EGLN2 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback